To include your compound in the COVID-19 Resource Center, submit it here.

Loxo begins rolling NDA for larotrectinib

Loxo Oncology Inc. (NASDAQ:LOXO) said it began a rolling NDA submission to FDA for larotrectinib (LOXO-101) to treat

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE